European Journal of Cancer
Volume 46, Issue 16 , Pages 3016-3021 , November 2010

Early cessation of the clinical development of LiPlaCis, a liposomal cisplatin formulation

  • Maja J.A. de Jonge

      Affiliations

    • Erasmus University Medical Center Daniel Den Hoed Cancer Center, Department of Medical Oncology, Rotterdam, The Netherlands
    • Authors contributed equally.
    • Corresponding Author InformationCorresponding author: Tel.: +31 10 439 1760; fax: +31 10 439 1003.
    • ,
  • Marije Slingerland

      Affiliations

    • Leiden University Medical Center, Department of Clinical Oncology, Leiden, The Netherlands
    • Authors contributed equally.
    • ,
  • Walter J. Loos

      Affiliations

    • Erasmus University Medical Center Daniel Den Hoed Cancer Center, Department of Medical Oncology, Rotterdam, The Netherlands
    • ,
  • Erik A.C. Wiemer

      Affiliations

    • Erasmus University Medical Center Daniel Den Hoed Cancer Center, Department of Medical Oncology, Rotterdam, The Netherlands
    • ,
  • Herman Burger

      Affiliations

    • Erasmus University Medical Center Daniel Den Hoed Cancer Center, Department of Medical Oncology, Rotterdam, The Netherlands
    • ,
  • Ron H.J. Mathijssen

      Affiliations

    • Erasmus University Medical Center Daniel Den Hoed Cancer Center, Department of Medical Oncology, Rotterdam, The Netherlands
    • ,
  • Judith R. Kroep

      Affiliations

    • Leiden University Medical Center, Department of Clinical Oncology, Leiden, The Netherlands
    • ,
  • Margret A.G. den Hollander

      Affiliations

    • Leiden University Medical Center, Department of Clinical Oncology, Leiden, The Netherlands
    • ,
  • Diane van der Biessen

      Affiliations

    • Erasmus University Medical Center Daniel Den Hoed Cancer Center, Department of Medical Oncology, Rotterdam, The Netherlands
    • ,
  • Mei-Ho Lam

      Affiliations

    • Erasmus University Medical Center Daniel Den Hoed Cancer Center, Department of Medical Oncology, Rotterdam, The Netherlands
    • ,
  • Jaap Verweij

      Affiliations

    • Erasmus University Medical Center Daniel Den Hoed Cancer Center, Department of Medical Oncology, Rotterdam, The Netherlands
    • ,
  • Hans Gelderblom

      Affiliations

    • Leiden University Medical Center, Department of Clinical Oncology, Leiden, The Netherlands

Received 31 May 2010 ,Accepted 14 July 2010.

References 

  1. de Jongh FE, van Veen RN, Veltman SJ, et al. Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients. Br J Cancer. 2003;88(8):1199–1206
  2. Go RS, Adjei AA. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol. 1999;17(1):409–422
  3. Planting AS, van der Burg ME, de Boer-Dennert M, Stoter G, Verweij J. Phase I/II study of a short course of weekly cisplatin in patients with advanced solid tumours. Br J Cancer. 1993;68(4):789–792
  4. Zamboni WC. Concept and clinical evaluation of carrier-mediated anticancer agents. Oncologist. 2008;13(3):248–260
  5. White SC, Lorigan P, Margison GP, et al. Phase II study of SPI-77 (sterically stabilised liposomal cisplatin) in advanced non-small-cell lung cancer. Br J Cancer. 2006;95(7):822–828
  6. Zamboni WC, Gervais AC, Egorin MJ, et al. Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma. Cancer Chemother Pharmacol. 2004;53(4):329–336
  7. Laye JP, Gill JH. Phospholipase A2 expression in tumours: a target for therapeutic intervention?. Drug Discov Today. 2003;8(15):710–716
  8. Abe T, Sakamoto K, Kamohara H, et al. Group II phospholipase A2 is increased in peritoneal and pleural effusions in patients with various types of cancer. Int J Cancer. 1997;74(3):245–250
  9. Andresen TL, Jensen SS, Jorgensen K. Advanced strategies in liposomal cancer therapy: problems and prospects of active and tumor specific drug release. Prog Lipid Res. 2005;44(1):68–97
  10. Jensen SS, Andresen TL, Davidsen J, et al. Secretory phospholipase A2 as a tumor-specific trigger for targeted delivery of a novel class of liposomal prodrug anticancer etherlipids. Mol Cancer Ther. 2004;3(11):1451–1458
  11. <http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf>.
  12. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment of solid tumours. J Natl Cancer Inst. 2000;92:205–216
  13. de Jonge MJ, Loos WJ, Gelderblom H, et al. Phase I pharmacologic study of oral topotecan and intravenous cisplatin: sequence-dependent hematologic side effects. J Clin Oncol. 2000;18(10):2104–2115
  14. Kwaan HC, Gordon LI. Thrombotic microangiopathy in the cancer patient. Acta Haematol. 2001;106(1–2):52–56
  15. Stathopoulos GP, Boulikas T, Vougiouka M, et al. Pharmacokinetics and adverse reactions of a new liposomal cisplatin (Lipoplatin): phase I study. Oncol Rep. 2005;13(4):589–595
  16. Koukourakis MI, Giatromanolaki A, Pitiakoudis M, et al. Concurrent liposomal cisplatin (Lipoplatin), 5-fluorouracil and radiotherapy for the treatment of locally advanced gastric cancer: a phase I/II study. Int J Radiat Oncol Biol Phys. 2010;[Epub ahead of print]
  17. Alberts DS, Garcia DJ. Safety aspects of pegylated liposomal doxorubicin in patients with cancer. Drugs. 1997;54(Suppl. 4):30–45
  18. Urien S, Brain E, Bugat R, et al. Pharmacokinetics of platinum after oral or intravenous cisplatin: a phase 1 study in 32 adult patients. Cancer Chemother Pharmacol. 2005;55(1):55–60
  19. Meerum Terwogt JM, Groenewegen G, Pluim D, et al. Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin. Cancer Chemother Pharmacol. 2002;49(3):201–210
  20. Reece PA, Stafford I, Russell J, Gill PG. Reduced ability to clear ultrafilterable platinum with repeated courses of cisplatin. J Clin Oncol. 1986;4(9):1392–1398

☆ This clinical trial was registered as EUDRACT 2006-006637-40.

PII: S0959-8049(10)00693-3

doi: 10.1016/j.ejca.2010.07.015

European Journal of Cancer
Volume 46, Issue 16 , Pages 3016-3021 , November 2010

Article Tools

* Image Usage & Resolution